TRUP has been the subject of several other research reports. Northland Securities cut shares of Trupanion from an outperform rating to a market perform rating and upped their target price for the company from $42.00 to $50.00 in a report on Wednesday, August 5th. They noted that the move was a valuation call. Canaccord Genuity upped their price objective on shares of Trupanion from $58.00 to $62.00 and gave the company a buy rating in a research note on Wednesday, August 5th. Stifel Nicolaus lifted their target price on Trupanion from $33.00 to $43.00 and gave the stock a hold rating in a research report on Thursday, July 30th. ValuEngine raised Trupanion from a hold rating to a buy rating in a research report on Monday, October 12th. Finally, Lake Street Capital lifted their price target on Trupanion from $50.00 to $67.00 and gave the stock a buy rating in a research report on Wednesday, August 5th. Five research analysts have rated the stock with a hold rating and five have assigned a buy rating to the company’s stock. Trupanion currently has a consensus rating of Buy and an average target price of $53.00.
Trupanion stock opened at $73.20 on Friday. The stock has a market cap of $2.58 billion, a PE ratio of 1,464.29 and a beta of 1.54. The company has a debt-to-equity ratio of 0.19, a current ratio of 1.63 and a quick ratio of 1.63. The stock’s fifty day moving average is $78.52 and its two-hundred day moving average is $51.20. Trupanion has a 1-year low of $22.48 and a 1-year high of $95.53.
In other news, Director Robin A. Ferracone sold 15,000 shares of Trupanion stock in a transaction dated Wednesday, August 12th. The shares were sold at an average price of $62.53, for a total value of $937,950.00. Following the sale, the director now owns 111,258 shares of the company’s stock, valued at $6,956,962.74. The sale was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink. Also, insider Gavin Friedman sold 300 shares of the business’s stock in a transaction dated Monday, October 19th. The stock was sold at an average price of $92.70, for a total transaction of $27,810.00. Following the transaction, the insider now owns 466 shares in the company, valued at $43,198.20. The disclosure for this sale can be found here. In the last three months, insiders sold 111,693 shares of company stock worth $7,760,220. Corporate insiders own 13.61% of the company’s stock.
Institutional investors and hedge funds have recently made changes to their positions in the business. Ingalls & Snyder LLC purchased a new position in shares of Trupanion during the 3rd quarter worth approximately $7,101,000. Nisa Investment Advisors LLC acquired a new stake in Trupanion in the third quarter valued at $67,000. Louisiana State Employees Retirement System purchased a new stake in shares of Trupanion during the 3rd quarter worth $1,184,000. Hamilton Lane Advisors LLC grew its stake in shares of Trupanion by 57.4% during the 3rd quarter. Hamilton Lane Advisors LLC now owns 21,902 shares of the financial services provider’s stock worth $1,728,000 after purchasing an additional 7,983 shares during the period. Finally, Beaumont Asset Management L.L.C. acquired a new position in shares of Trupanion during the 3rd quarter worth $296,000. 91.98% of the stock is currently owned by institutional investors.
Trupanion, Inc, together with its subsidiaries, provides medical insurance for cats and dogs on monthly subscription basis in the United States, Canada, and Puerto Rico. The company operates through Subscription Business and Other Business segments. It serves pet owners and veterinarians through third-party referrals and online member acquisition channels.
Featured Article: What Are Treasury Bonds?
Receive News & Ratings for Trupanion Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Trupanion and related companies with MarketBeat.com's FREE daily email newsletter.